Depth of Response and Progression-Free Survival in CLL Patients on Ibrutinib

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：8 / 9
页数：2
相关论文
共 50 条
  • [21] A Nomogram for Predicting Progression-free Survival in Patients with Endometrial Cancer
    Wang, Z.
    Zhao, Z.
    Li, W.
    Bao, X.
    Liu, T.
    Yang, X.
    CLINICAL ONCOLOGY, 2023, 35 (09) : e516 - e527
  • [22] Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy
    Guedes, Nayara Ribeiro
    Da Fonseca, Ana Rita
    Carneiro, Thiago Xavier
    de Molla, Vinicius Campos
    Silva, Rodrigo Santucci
    Fortier, Sergio Costa
    de Piratininga Figueiredo, Vera Lucia
    Ommati, Larissa
    Buccheri, Valeria
    Oliveira, Gislaine Borba
    Perobelli, Leila Martins
    Blumm Ferreira, Fernando Sergio
    Vescovi, Matheus
    Arrais-Rodrigues, Celso
    BLOOD, 2019, 134
  • [23] Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors
    Memmott, Regan M.
    Wolfe, Adam R.
    Carbone, David P.
    Williams, Terence M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (07) : 1086 - 1098
  • [24] Impact of Race on Progression-Free Survival and Overall Survival in Patients with Multiple Myeloma
    Wani, Kashmira
    Gutta, Radhika
    Mittal, Aayush
    Jamil, Maria
    Springer, Kylie
    Kuriakose, Philip
    BLOOD, 2023, 142
  • [25] Complete Response Linked to Progression-Free Survival in Chronic Lymphocytic Leukemia
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 92 - 92
  • [26] Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival
    Merino, Margret
    Kasamon, Yvette
    Theoret, Marc
    Pazdur, Richard
    Kluetz, Paul
    Gormley, Nicole
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2706 - +
  • [27] The depth of response was associated with the progression-free survival in advanced non-small cell lung cancer patients treated with EGFR-TKI
    Liu, Yutao
    Zhang, Kai
    Li, Chengcheng
    Hu, Xingsheng
    Jiang, Jun
    Hao, Xuezhi
    Wang, Yan
    Li, Junling
    Xing, Puyuan
    Yang, Sheng
    Zhang, Xin
    Wang, Guoqiang
    Cai, Shangli
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Depth of Response was Associated with Progression-Free Survival in Patients with Advanced Non-small Cell Lung Cancer treated with EGFR-TKI
    Liu, Yu-Tao
    Zhang, Kai
    Li, Cheng-Cheng
    Hu, Xing-Sheng
    Jiang, Jun
    Hao, Xue-Zhi
    Wang, Yan
    Li, Jun-Ling
    Xing, Pu-Yuan
    Yang, Sheng
    Zhang, Xin
    Wang, Guo-Qiang
    Cai, Shang-Li
    Shi, Yuan-Kai
    JOURNAL OF CANCER, 2019, 10 (21): : 5108 - 5113
  • [29] A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL
    Dimier, Natalie
    Delmar, Paul
    Ward, Carol
    Morariu-Zamfir, Rodica
    Fingerle-Rowson, Guenter
    Bahlo, Jasmin
    Fischer, Kirsten
    Eichhorst, Barbara
    Goede, Valentin
    van Dongen, Jacques J. M.
    Ritgen, Matthias
    Boettcher, Sebastian
    Langerak, Anton W.
    Kneba, Michael
    Hallek, Michael
    BLOOD, 2018, 131 (09) : 955 - 962
  • [30] Minimal residual disease and its association with overall and progression-free survival in CLL: a systematic literature review
    Johnston, Raymond
    Furber, Alexandra
    Springate, Cassie
    Yu, Ning
    LEUKEMIA & LYMPHOMA, 2020, 61 : 80 - 81
12345